Skip to content
Serving university laboratories & diagnostic developers in the EU & US
sales@medical-ivd.com  |  WhatsApp
Home / Choosing a cTnI Antigen for Assay Development
Resource

Choosing a cTnI Antigen for Assay Development

Antigen source, form and stability shape the calibration curve in cardiac troponin I immunoassays. Practical points for assay developers.

Why the Antigen Form Matters

Cardiac troponin I (cTnI) is a cardiac-specific protein used in immunoassays for myocardial injury. Native cTnI circulates in several forms, including binary and ternary complexes with troponin C and troponin T, and undergoes phosphorylation and proteolytic modification. Recombinant cTnI antigens differ in whether they reproduce these modifications and in their own stability. Because antibodies are raised against defined epitopes, the antigen used for calibration and the epitopes recognised by the antibody pair should be considered together rather than independently.

Calibrator and Standardisation Considerations

Troponin assays are not yet fully harmonized across platforms, and calibration traces to different reference materials. When developing an assay, record the source and form of the cTnI used as calibrator, the matrix it is diluted into, and how the curve is anchored. Complexing cTnI with troponin C can stabilise certain epitopes and is used in some commercial systems. The choice affects the relationship between signal and concentration, so it is best fixed early and written into the development file. Two suppliers may describe the same nominal antigen while differing in how it is presented, so the written record is what allows the choice to be revisited later.

Stability During Development

Recombinant cTnI can adsorb to surfaces and is sensitive to freeze—thaw cycling. Define an aliquot size that avoids repeated thawing, and characterise the working concentration range in your own buffer before locking the calibrator format. A short in-house stability check, comparing freshly thawed material with an aged aliquot in the same assay, will show whether the antigen or the matrix is drifting. Apple and colleagues set out the analytical issues governing cardiac marker assays in Clinical Chemistry (2007).

Ask a technical question

Request a Quote or Sample

Tell us your application, target purity and quantity — we reply within one business day.

© 2026 Hainan Medikament Trading Co., Ltd. All rights reserved.
For research use and in-vitro diagnostic development only · Privacy · Terms of Sale